Skip to content

Pharmacokinetic Properties of Single- and Multiple-Dose metolazone Tablets in Healthy Chinese Volunteers

Pharmacokinetic Properties of Single- and Multiple-Dose metolazone Tablets in Healthy Chinese Volunteers

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-17012929
Enrollment
Unknown
Registered
2017-10-10
Start date
2014-09-10
Completion date
Unknown
Last updated
2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Medium dose group:Medium dose
High dose group:High dose

Sponsors

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy volunteers, half male and half female; 2. Aged 18 to 45 years; 3. Body mass index (BMI) in 19-24[BMI= weight / height (kg) 2 (M2)] within the scope of their weight should be similar with a group of volunteers; 4. Good health, heart, liver, kidney, digestive tract, nervous system and mental disorders and metabolic disorders and other medical history; 5. Voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: Subjects were excluded from the study if they had any allergies or history of cardiopathic, pulmonary, renal, hepatic, gastrointestinal, or hematologic abnormality or any other acute or chronic disease. Other exclusion criteria included exposure to any investigational medication within 30 days of the first dose of study medication, pregnant or nursing women, and women of childbearing potential not using a highly effective method of birth control.

Countries

China

Contacts

Public ContactZheng Hen

Tongji Medical College of Huazhong University of Science and Technology

345197887@qq.com+86 13072952081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 8, 2026